Bio-Path Holdings, Inc. · OTC:BPTH
Bio-Path — Investor Presentation (May 2022)
12 slides from Bio-Path's investor presentation, May 2022
Slide 1: Bio-Path Holdings: An Oncology-Focused Biotechnology Company
Bio-Path Holdings An Oncology-Focused Biotechnology Company May 2022
Slide 2: Forward looking statements
Forward looking statements This Presentation contains forward-looking statements with respect to business conducted by Bio-Path Holdings, Inc. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will
Slide 3: Introducing Bio-Path Holdings
Introducing Bio-Path Holdings Advanced Oligonucleotide Therapeutics with High Efficiency Systemic Delivery Publicly traded Employees, Established NASDAQ Contractors & Houston, TX Consultants BPTH 2007 14 Technology Highlights ® DNAbilize Technology, next generation single-stranded DNA antisense Robu
Slide 4: Robust Oncology Pipeline
Robust Oncology Pipeline Preclinical IND PHASE 1 PHASE 2 Prexigebersen (BP1001, Liposomal Grb2) AML* *Orphan drug designation from the USFDA and BP1001-A Solid Tumors (ovarian, endometrial, EMA for AML pancreatic) BP1002 (Liposomal Bcl-2) Lymphoma, CLL BP1002 (Liposomal Bcl-2) AML venetoclax failure
Slide 5: DNAbilize Technology
DNAbilize Technology ® Proven As Safe, Robust and Targeted Method for Treating Disease No Toxicity No Toxicity With human patients to date in prexigebersen clinical trial. • DNAbilize™ liposome structure is similar to the cellular membrane • P-ethoxy DNA does not induce hepatotoxicity or thrombocyto
Slide 6: Stage 1 of the Phase 2 Efficacy Trial Design for AML Prexigebersen Combination Therapy
Stage 1 of the Phase 2 Efficacy Trial Design for AML Prexigebersen Combination Therapy • Treatment of untreated AML patients who are induction therapy ineligible and unfit for stem cell transplant • Efficacy trial conducted at 6 leading cancer centers in the U.S., including the MD Anderson Cancer Ce
Slide 7: Data from Ongoing Phase 2 Study of Prexigebersen at 2021 ASH Annual Meeting
Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual Meeting Prexigebersen Data Show Signs of Safety and Efficacy in High Risk AML Patients In the Poster we report the safety run-in and efficacy data of AML patients treated with prexigebersen + decitabin
Slide 8: Experienced Leadership Team
Experienced Leadership Team Officer and Director Peter Nielsen since founding Michael Hickey 20+ years experience across all phases of drug Co-Founder, President, Company in 2007 Director Clinical development Chief Executive Officer Program Management and Chief Financial Manufacturing Officer Point
Slide 9: Scientific Advisory Board
Scientific Advisory Board Jorge Cortes, M.D. • Director, Cancer Center at Augusta University • Georgia Research Alliance Eminent Scholar in Cancer Chairman • Formerly, Jane and John Justin Distinguished Chair in Leukemia Research, Chief of the AML and CML sections, and Deputy Chair of the Department
Slide 10: IP and Financial Snapshot
IP and Financial Snapshot Intellectual Property • Original patents licensed from MD Anderson • New composition and methods of use patent issued covers DNAbilize® technology, solely owned by Bio-Path • Five patents issued in the U.S.; two foreign patents issued • Six additional applications pending i
Slide 11: Accomplishments in 2021
Accomplishments in 2021 We presented a poster at the 2021 American Association for Cancer Research (AACR) Annual Meeting in April that summarized preclinical studies that demonstrated the effectiveness of BP1002 + decitabine combination treatment in venetoclax resistant cells opening potential new
Slide 12: Thank you
Bio-Path Holdings Thank you Bio-Path Holdings, Inc. 4710 Bellaire Blvd Suite 210 Bellaire, TX 77401 Web: www.biopathholdings.com Mail: partnering@biopathholdings.com Tel: (832) 742-1369 12